MX2023001199A - Antagonistas de receptor nk para pacientes con cancer. - Google Patents

Antagonistas de receptor nk para pacientes con cancer.

Info

Publication number
MX2023001199A
MX2023001199A MX2023001199A MX2023001199A MX2023001199A MX 2023001199 A MX2023001199 A MX 2023001199A MX 2023001199 A MX2023001199 A MX 2023001199A MX 2023001199 A MX2023001199 A MX 2023001199A MX 2023001199 A MX2023001199 A MX 2023001199A
Authority
MX
Mexico
Prior art keywords
receptor antagonists
cancer patients
cancer
vms
attenuating
Prior art date
Application number
MX2023001199A
Other languages
English (en)
Inventor
D Christopher Schelling
Robert A Steiner
Susan D Reed
Victor M Navarro
Original Assignee
Acer Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acer Therapeutics Inc filed Critical Acer Therapeutics Inc
Publication of MX2023001199A publication Critical patent/MX2023001199A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción se refiere en general a un método para bloquear, atenuar o limitar el desarrollo de uno o más síntomas vasomotores (SVM) en un paciente que tiene cáncer, ha tenido cáncer o tiene un mayor riesgo de cáncer mediante la administración de un antagonista de NK.
MX2023001199A 2020-07-30 2021-07-30 Antagonistas de receptor nk para pacientes con cancer. MX2023001199A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063059086P 2020-07-30 2020-07-30
US202163134542P 2021-01-06 2021-01-06
PCT/US2021/044016 WO2022026900A2 (en) 2020-07-30 2021-07-30 Nk receptor antagonists for cancer patients

Publications (1)

Publication Number Publication Date
MX2023001199A true MX2023001199A (es) 2023-03-13

Family

ID=80036164

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023001199A MX2023001199A (es) 2020-07-30 2021-07-30 Antagonistas de receptor nk para pacientes con cancer.

Country Status (5)

Country Link
US (1) US20230277518A1 (es)
AU (1) AU2021315801A1 (es)
CA (1) CA3189841A1 (es)
MX (1) MX2023001199A (es)
WO (1) WO2022026900A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023147134A2 (en) * 2022-01-31 2023-08-03 Acer Therapeutics, Inc. Methods for treating patients having low estrogen with nk3 antagonists
WO2023211779A1 (en) * 2022-04-25 2023-11-02 Kallyope, Inc. Treatment of headache disorders with nk3 modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201315846D0 (en) * 2013-09-05 2013-10-23 Imp Innovations Ltd Method for treating or preventing hot flushes
US20150258080A1 (en) * 2014-03-13 2015-09-17 Genentech, Inc. Therapeutic combinations with estrogen receptor modulators

Also Published As

Publication number Publication date
CA3189841A1 (en) 2022-02-03
WO2022026900A3 (en) 2022-04-21
WO2022026900A2 (en) 2022-02-03
US20230277518A1 (en) 2023-09-07
AU2021315801A1 (en) 2023-02-23

Similar Documents

Publication Publication Date Title
MX2023001199A (es) Antagonistas de receptor nk para pacientes con cancer.
MX2020005651A (es) Receptor de antigeno quimerico dirigido a bcma y usos del mismo.
BR112020016331A8 (pt) Métodos para tratar câncer com anticorpos anti-pd-1
MA32907B1 (fr) Régime posologique d'un agoniste du récepteur s1p
MX2018011054A (es) Metodos para tratar cancer de mama er+, her2-, hrg+ usando terapias de combinacion que comprenden un anticuerpo anti-erbb3.
PH12020551425A1 (en) Rimegepant for cgrp related disorders
TW200605907A (en) Preventing autoimmune disease
UA115145C2 (uk) КАРБОКСАМІД- АБО СУЛЬФОНАМІДЗАМІЩЕНІ АЗОТОВМІСНІ 5-ЧЛЕННІ ГЕТЕРОЦИКЛИ ЯК МОДУЛЯТОРИ ОРФАНОВОГО ЯДЕРНОГО РЕЦЕПТОРА RORγ
EA033400B1 (ru) Антитело против cd3 и его применение
BR112022000377A2 (pt) Métodos para o tratamento de dermatite atópica por administração de antagonista de il-4r
CL2017001756A1 (es) Régimen de dosificación para antagonistas de madcam.
MX2022014440A (es) Metodos para el tratamiento de la esofagitis eosinofilica mediante la administracion de un inhibidor de il-4r.
BR112020015915A8 (pt) Usos de um anticorpo anti-pd-1 e um anticorpo anti-ctla4 ou fragmentos de ligação ao antígeno dos mesmos, bem como kit para tratamento de um paciente com câncer
MX2020009668A (es) Métodos novedosos.
MX2020013335A (es) Metodos novedosos.
MX2021008268A (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r.
MX2022004678A (es) Anticuerpo anti-beta amiloide para el tratamiento de la enfermedad de alzheimer.
MX2021004883A (es) Metodos y composiciones para tratar apnea del sue?o.
JOP20220057A1 (ar) علاج أمراض أو اضطرابات الكبد تشتمل على مضادات مستقبل actrii
MX2022016341A (es) Formas farmaceuticas de maleato de acalabrutinib.
MX2022008216A (es) Tratamiento de cancer en combinacion usando un antagonista de pd-1, un antagonista de ilt4 y lenvatinib o sales del mismo.
MX2022001396A (es) Metodos para tratar trastornos asociados con niveles elevados de anticuerpos que interactuan con el receptor de nmda.
MX2022007516A (es) Metodos para tratar el cancer utilizando una combinacion de un antagonista de muerte programada-1, un antagonista de transcripto 4 similar a inmunoglobulina y agentes quimioterapeuticos.
MX2024004762A (es) Metodos para el tratamiento del prurigo nodular mediante la administracion de un antagonista de il-4r.
MX2021004120A (es) Regimen de dosificacion para antagonistas de tfpi.